Pegvisomant

Pegvisomant is an analog of human GH, acts as a competitive inhibitor of the GH receptor.

Indications

Second or third-line therapy to control the metabolic effects of acromegaly in patients who did not achieve a biochemical remission after surgery and/or radiation therapy. Can be used alone or in combination with SRLs and/or cabergoline.

Effectiveness

IGF-1 normalization in ~ 60% of patients.

Dose

Loading dose 40 mg subq once. Starting 10 mg/day. Max 30 mg/day.

Monitoring and Adjustment

Adverse Reactions

References